Abstract: Biocompatible, bioerodible implants and microspheres include latanoprost and a biodegradable polymer effective, when placed intraocular (such as into the subtenon space) to treat glaucoma.
Type:
Grant
Filed:
July 3, 2014
Date of Patent:
November 5, 2019
Assignee:
Allergan, Inc.
Inventors:
Michael R. Robinson, Hui Liu, Patrick M. Hughes, Lon T. Spada, Alazar N. Ghebremeskel
Abstract: Rapid, animal protein free, chromatographic processes and systems for obtaining high potency, high yield botulinum neurotoxin for research, therapeutic and cosmetic use.
Type:
Grant
Filed:
July 31, 2017
Date of Patent:
November 5, 2019
Assignee:
Allergan, Inc.
Inventors:
Jennifer L. Ton, Hemant A. Patel, Ronald C. Bates, Wajdie M. Ahmad
Abstract: The present specification discloses methods of treating a psychological trauma in an individual using botulinum toxins and/or a Targeted Exocytosis Modulator, and compositions thereof.
Abstract: The present specification discloses methods for detecting extremely low amounts of botulinum neurotoxin serotype A in samples, including complex matrices like blood, plasma, and serum.
Abstract: Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
Type:
Grant
Filed:
October 6, 2015
Date of Patent:
October 15, 2019
Assignee:
Allergan, Inc.
Inventors:
Lon T. Spada, James N. Chang, Michelle H. Luu
Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, which protease is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent (eg clostridial neurotoxin L-chain or IgA protease); a galanin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent (eg GALR1, GALR2, or GALR3 receptor); a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease and the galanin Targeting Moiety; a translocation domain that is capable of translocating the protease from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent (eg HN domain of clostridial neurotoxin); a first spacer located between the non-cytotoxic protease and the prote
Type:
Application
Filed:
May 20, 2019
Publication date:
October 10, 2019
Applicants:
IPSEN BIOINNOVATION LIMITED, ALLERGAN, INC.
Inventors:
Peter JAMES, Keith FOSTER, John CHADDOCK, Roger AOKI, Lance STEWARD
Abstract: The present invention relates to a method for treating dermal inflammation and dermal diseases by local or systemic delivery, in a subject in need of such treatment, which comprises administering a pharmaceutical composition comprising a therapeutically effective amount of at least one agonist of Formyl peptide receptor 2 (FPR2).
Type:
Grant
Filed:
April 18, 2017
Date of Patent:
October 8, 2019
Assignee:
ALLERGAN, INC.
Inventors:
Veena Viswanath, Richard L. Beard, John E. Donello, Edward Hsia
Abstract: Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.
Type:
Grant
Filed:
October 9, 2017
Date of Patent:
October 8, 2019
Assignee:
Allergan, Inc.
Inventors:
Xiaojie Yu, Nicholas J. Manesis, Jacob Pollock
Abstract: Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such as botulinum neurotoxin, to the patient, are provided.
Type:
Grant
Filed:
March 2, 2018
Date of Patent:
September 24, 2019
Assignee:
Allergan, Inc.
Inventors:
Ivan Aguilar, Gustavo M. Gaxiola, Gilberto P. Paz
Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the polymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Type:
Grant
Filed:
June 5, 2017
Date of Patent:
September 10, 2019
Assignee:
Allergan, Inc.
Inventors:
Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
Abstract: Described herein are compounds that are EP4 agonists and antagonists which are useful for treating a variety of pathological conditions associated with activity of EP4 receptors.
Abstract: Methods for treating a patient suffering from a medication overuse headache disorder are provided. The methods comprise administering to a patient suffering from a medication overuse disorder a Clostridial toxin. The toxin is administered to the frontalis, corrugator, procerus, occipitalis, temporalis, trapezius and cervical paraspinal muscles of the patient.
Type:
Grant
Filed:
September 18, 2017
Date of Patent:
September 10, 2019
Assignee:
Allergan, Inc.
Inventors:
Catherine C. Turkel, Sheena K. Aurora, Mitchell F. Brin
Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
Abstract: The present specification discloses porous materials, methods of forming such porous materials, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices.
Type:
Grant
Filed:
September 1, 2015
Date of Patent:
August 27, 2019
Assignee:
ALLERGAN, INC.
Inventors:
Futian Liu, Nicholas J. Manesis, Alexei Goraltchouk, Dimitri Stroumpoulis
Abstract: The present invention provides a compound, that is a 1-({halo-2-[(2-hydrocarbyl or substituted hydrocarbyl)oxy]phenyl}methyl)-(fused bicyclic nitrogen heteroaryl) carboxylic acid or an ester or sulfonamide thereof. The compound may be represented by the following formula Wherein R1, R2, R3, R4 A, X, W, Z and Y are as defined in the specification. The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.
Type:
Grant
Filed:
January 13, 2017
Date of Patent:
August 27, 2019
Assignee:
ALLERGAN, INC.
Inventors:
William R. Carling, Jose L. Martos, Jussi J. Kangasmetsa, Jenny W. Wang, David F. Woodward
Abstract: A topical pharmaceutical composition comprising tazarotene and one or more of an anti-inflammatory or anti-bacterial agent. Also provided is a method for treating skin conditions, such as acne utilizing the above topical pharmaceutical composition.
Type:
Grant
Filed:
July 20, 2015
Date of Patent:
August 20, 2019
Assignee:
Allergan, Inc.
Inventors:
Michael G. Oefelein, Jeffrey R. Ehrhardt, Gurpreet Ahluwalia
Abstract: Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions comprise a surfactant selected from a poloxamer and a polysorbate; an antioxidant selected from methionine, N-acetyl cysteine, ethylenediaminetetraacetic acid and combinations thereof; and, optionally, a tonicity agent and/or a lyoprotector selected from, for example, trehalose and sucrose.
Type:
Application
Filed:
September 13, 2017
Publication date:
August 15, 2019
Applicant:
Allergan, Inc.
Inventors:
Maurice Abiad, Bhas Dani, Evgenyi Shalaev